PRNewsWire
20 Aug 2026, 13:28 UTC · 12h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Regeneron's Phase 3 clinical trial of Fianlimab in combination with Libtayo for melanoma failed to reach statistical significance for its primary endpoint of progression-free survival. — The failure of a 'potential blockbuster' drug candidate directly removes future revenue growth expectations and previously wiped $11 billion from the market cap.
-0.80A securities class action lawsuit has been filed alleging Regeneron misled investors about the trial's progress and failed to disclose flawed statistical assumptions. — Litigation creates ongoing legal liability and potential financial settlements, while damaging management credibility.
-0.40Regeneron altered the trial protocol due to slow event rates and submitted these changes to regulatory authorities months before informing investors. — The delay in disclosure suggests a lack of transparency that can increase the risk of regulatory scrutiny and investor distrust.
-0.30Continue reading
6 related stories
Search tags
Which stocks this story touches
The company is facing a class action lawsuit following a failed Phase 3 clinical trial and an $11 billion loss in market capitalization.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
2h ago
